An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan

Trial Profile

An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2015

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 28 Sep 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Glatiramer acetate (Copaxone) subcutaneous injection 20 mg syringe for the treatment of multiple sclerosis. The approval is based on the results of this and three other overseas clinical trials conducted by Teva in patients with relapsing- remitting multiple sclerosis.
    • 30 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top